Stock Ratings / Health Care / OGEN / earnings

GNPX (47) PPBT (61) KAPA (37) MTNB (35) ⌘ Pro Terminal →

Oragenics Inc. (OGEN) Next Earnings Date & Expected ±11.7% Move

Q: When is OGEN's next earnings date?

Based on SEC filing cadence, Oragenics Inc. (OGEN)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is OGEN stock expected to move on earnings?

Volatility modeling currently projects a ±11.7% event move for OGEN, spanning a range between $1 and $0.41.

$0.37 -0.05% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.37

Oragenics Inc. (OGEN) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OGEN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Oragenics Inc. (NYSE: OGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.37 (-0.05% 1D, market cap $1.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, OGEN ranks #449 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OGEN compare to GNPX and PPBT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGEN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GNPX (Genprex Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M) and PPBT (Purple Biotech Ltd.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $1.8M). Among the 5-stock peer group, OGEN leads on earnings multiple (N/A) while OGEN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OGEN?

▼

Per OGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001174940), Oragenics Inc. generated $0 in revenue, -$984.2M in net income, and -$9.2M in free cash flow against $10.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.37 (-0.20%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OGEN)Realized 20D OHLCV Swing Band: ±11.7%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY OGEN SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)

20D Institutional Volume Accumulation (±11.7% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.46-6.5% Next Q

Q2 (-2Q)

Grade D$0.43-2.3% Next Q

Q3 (-1Q)

Grade D$0.42-11.9% Next Q

Current

Grade D$0.37-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OGEN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OGEN currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.47) and Max Pain ($0.39) forces dealer call-delta covering toward $1.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±11.7% Swing Band

±$0.04 Expected Swing

MODEL EARNINGS SETUP GAUGE

OGEN Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$984.2M	-$9.2M	52%
FY 2024	2024-12-31	$0	-$1.06B	-$8.6M	52%
FY 2023	2023-12-31	$37.7K	-$20.7M	-$7.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OGEN)

✓Walkthrough of OGEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.29%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.37H $0.39L $0.37C $0.37VOL 9.2K

RES: $0.49SUP: $0.34SMA50: $0.47SMA200: $0.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OGEN Butterfly Map → + Track OGEN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OGEN)

Health Care Rank #449 of 1016 ⚔️ GNPX vs OGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OGEN vs. GNPX, PPBT, KAPA, MTNB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Oragenics Inc. (OGEN) ranks #449 by composite RQD confidence (44/100, grade D) and #1006 by equity capitalization ($1.7M). Within this direct 5-issuer industry benchmark cohort, OGEN leads on earnings valuation at N/A trailing P/E, while OGEN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with OGEN at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OGEN ACTIVE Oragenics Inc.	D	44/100	—	—	-35.0%	-0.05%	$1.7M	Benchmark Subject
GNPX Genprex Inc.	D	47/100	—	—	-35.0%	+9.80%	$1.7M	/gnpx-vs-ogen →
PPBT Purple Biotech Ltd.	C-	61/100	—	—	—	+7.34%	$1.8M	/ppbt-vs-ogen →
KAPA Kairos Pharma Ltd.	D-	37/100	—	—	-35.0%	-1.87%	$1.8M	/kapa-vs-ogen →
MTNB Matinas Biopharma Holdings Inc.	D-	35/100	—	—	-35.0%	-20.53%	$1.9M	/mtnb-vs-ogen →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001174940

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oragenics Inc. (OGEN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$984.2M, operating cash flow of -$9.2M, and free cash flow of -$9.2M (-7.5% YoY). On the balance sheet, OGEN closed FY2025 with $10.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$984.2M	-$9.2M	-$9.2M	$10.1M	—
FY2024 (FY)	2024-12-31	$0	-$1.06B	-$8.6M	-$8.6M	$1.5M	—
FY2023 (FY)	2023-12-31	$37.7K	-$20.7M	-$7.3M	-$7.3M	—	—

3. OGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OGEN compare to GNPX and PPBT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OGEN?

Where is OGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

OGEN last traded at $0.37 (-0.05% on volume of 9,216 shares), positioning the stock -21.28% below its 50-day simple moving average ($0.47) and -39.34% below its 200-day simple moving average ($0.61). Across its 52-week range of $0.35 to $1.23, OGEN sits at the 2.3% percentile with a 14-day RSI of 28.1 (OVERSOLD (<32)) and an implied next-earnings move of ±11.7% ($1.00 to $0.41).

OGEN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is OGEN's next earnings date?

Based on SEC filing cadence, Oragenics Inc. (OGEN)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is OGEN stock expected to move on earnings?

Volatility modeling currently projects a ±11.7% event move for OGEN, spanning a range between $1 and $0.41.

Direct Sub-Reports: OGEN RQD Cockpit OGEN 12M Forecast OGEN Earnings & Move OGEN Dividends & DRIP OGEN Insiders & 13F OGEN Whale Options OGEN Profit Sankey OGEN News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

OGEN — Oragenics Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:24Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Oragenics Inc. (OGEN) carries a composite score of 44/100 (D — Roarable Sell — Underperform / Distribution Warning) at a current price of $0.37 (-0.05%). Fundamental cash generation scores 6/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 13/20, insider conviction scores 5/20, macro regime alignment scores 10/20 (Beta 1.00), and forensic balance-sheet protection scores 10/20 (Altman Z-Score N/A, Piotroski F-Score 2/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (—) and free cash flow conversion relative to the 52-week range of $0.35 – $1.23.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), OGEN is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

OGEN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Oragenics Inc. (OGEN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OGEN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 47d ago

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 65d ago

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platf

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 118d ago

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital — are now active and

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 168d ago

ORAGENICS PROVIDES INVESTOR UPDATE

A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has continued to execute

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 181d ago

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, to

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 203d ago

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 179d ago

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San Diego, CA, May 07,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 166d ago

Sidoti Events, LLC's May Micro-Cap Virtual Conference

NEW YORK, NY / ACCESS Newswire / May 20, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Virtual Investor Conference tak

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OGEN Bull vs. Bear Conversation Board — What's Your Call at $0.37?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OGEN 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.33 (-10.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is OGEN (D • RQD 44/100) a Buy at $0.37?

Welcome to the OGEN (Oragenics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.31 (-16.2%)

Spot @ $0.37

Pump the brakes on OGEN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on OGEN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Oragenics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.46 (+24.3%)

Spot @ $0.37

OGEN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on OGEN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.37 (52-wk range $0.35 - $1.23), any beat on forward guidance forces shorts and underweight funds to chase.